MARC보기
LDR02226nmm uu200397 4500
001000000332157
00520240805170139
008181129s2018 |||||||||||||||||c||eng d
020 ▼a 9780438239180
035 ▼a (MiAaPQ)AAI10954429
040 ▼a MiAaPQ ▼c MiAaPQ ▼d 248032
0820 ▼a 615
1001 ▼a Miller, Zachary C.
24514 ▼a The Development of Novel Non-Peptide Proteasome Inhibitors for the Treatment of Solid Tumors.
260 ▼a [S.l.] : ▼b University of Kentucky., ▼c 2018
260 1 ▼a Ann Arbor : ▼b ProQuest Dissertations & Theses, ▼c 2018
300 ▼a 143 p.
500 ▼a Source: Dissertation Abstracts International, Volume: 79-12(E), Section: B.
500 ▼a Adviser: Kyung Bo Kim.
5021 ▼a Thesis (Ph.D.)--University of Kentucky, 2018.
520 ▼a The proteasome is a large protein complex which is responsible for the majority of protein degradation in eukaryotes. Following FDA approval of the first proteasome inhibitor bortezomib for the treatment of multiple myeloma (MM) in 2003, there h
520 ▼a It is our hypothesis that compounds with non-peptidic structures, non-covalent and reversible modes of action, and unique selectivity profiles against the proteasome's distinct catalytic subunits could have superior pharmacodynamic and pharmacok
520 ▼a Our efforts began with a computational screen performed in the lab of Dr. Chang-Guo Zhan. This virtual screen narrowed a library of over 300,000 drug-like compounds down to under 300 virtual hits which were then screened for proteasome inhibitor
520 ▼a We believe that our lead compound as well as our drug discovery approach itself will be of interest and use to other researchers. We hope that this research effort may aid in the further development of reversible non-peptide proteasome inhibitor
590 ▼a School code: 0102.
650 4 ▼a Pharmaceutical sciences.
690 ▼a 0572
71020 ▼a University of Kentucky.
7730 ▼t Dissertation Abstracts International ▼g 79-12B(E).
773 ▼t Dissertation Abstract International
790 ▼a 0102
791 ▼a Ph.D.
792 ▼a 2018
793 ▼a English
85640 ▼u http://www.riss.kr/pdu/ddodLink.do?id=T15001222 ▼n KERIS
980 ▼a 201812 ▼f 2019
990 ▼a 관리자